DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinac (Benzoyl Peroxide Topical) - Summary

 
 



CLINAC SUMMARY

Clinac® BPO 7 (benzoyl peroxide) is a topical preparation containing 7% benzoyl peroxide as the active ingredient in a gel vehicle containing purified water, propylene glycol, Acrysorb™ (brand of acrylates copolymer), PEG-400, carbomer 940, disodium EDTA, and sodium hydroxide.

Clinac® BPO 7 is indicated for the topical treatment of mild to moderate acne vulgaris. Clinac® BPO 7 may be used with other acne treatments including retinoic acid products, antibiotics and sulfur/salicylic acid containing preparations.


See all Clinac indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Clinac (Benzoyl Peroxide Topical)

What's New in Acne and Rosacea
Source: Medscape Dermatology Headlines [2016.04.29]
Dr Hillary Baldwin summarizes the latest acne and rosacea news from the 2016 American Academy of Dermatology meeting.
Medscape Dermatology

Pregnancy Prevention Program in Acne Drug Users Ineffective
Source: Medscape Dermatology Headlines [2016.04.26]
Results suggest one or two children are born each year with birth defects related to isotretinoin and subpar contraceptive use.
Medscape Medical News

Contraception Safety Program for Acne Drug Failing in Canada
Source: MedicineNet Acne Specialty [2016.04.26]
Title: Contraception Safety Program for Acne Drug Failing in Canada
Category: Health News
Created: 4/25/2016 12:00:00 AM
Last Editorial Review: 4/26/2016 12:00:00 AM

Pregnancy guidelines for harmful acne drug not adhered to by many women
Source: Pregnancy / Obstetrics News From Medical News Today [2016.04.25]
A new study suggests around 30-50 percent of women who use the acne drug isotretinoin do not adhere to current pregnancy prevention guidelines.

Acne Drug: FDA Advisors Recommend OTC Adapalene
Source: MedPage Today Dermatology [2016.04.15]
(MedPage Today) -- Panel votes 16-0 that the drug is safe for use without a prescription.

more news >>

Published Studies Related to Clinac (Benzoyl Peroxide Topical)

The efficacy, safety, and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris: a randomized trial. [2013]
Topical treatments, such as adapalene and benzoyl peroxide (BPO), are popular in mild-to-moderate acne vulgaris... Both topical adapalene 0.1% and BPO 2.5% gels seem safe and effective in mild acne vulgaris, with a marginal tendency toward the former.

Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. [2011.11]
BACKGROUND: Topical therapy with comedolytics and antibiotics are often advocated for mild and moderate severity acne vulgaris. Nadifloxacin, a new fluoroquinolone with anti-Propionibacterium acnes activity and additional anti-inflammatory activity, is approved for use in acne. This randomized controlled assessor blind trial compared the clinical effectiveness and safety of eight weeks therapy of nadifloxacin 1% versus clindamycin 1% as add-on therapy to benzoyl peroxide (2.5%) in mild to moderate grade acne... CONCLUSIONS: Topical nadifloxacin, a new fluoroquinolone is effective, tolerable, and safe for mild o moderate facial acne. Its clinical effectiveness is comparable to clindamycin when used as add-on therapy to benzoyl peroxide.

Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. [2011.08]
BACKGROUND: Oral antibiotics in association with a topical retinoid with or without benzoyl peroxide (BPO) are the recommended first-line option in the treatment of moderate to severe acne vulgaris. OBJECTIVES: To evaluate the efficacy and safety of oral lymecycline 300 mg with adapalene 0.1%-BPO 2.5% (A/BPO) fixed-dose gel in comparison with oral lymecycline 300 mg with a vehicle gel in subjects with moderate to severe acne vulgaris... CONCLUSION: These results demonstrate the clinical benefit of combining A/BPO with lymecycline in the treatment of moderate to severe acne vulgaris. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.

Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, doubleblind, placebo-controlled trial. [2011.02]
BACKGROUND: Progressive macular hypomelanosis is a dermatosis without definite etiology. There is no consensus or first-line therapy in the treatment of progressive macular hypomelanosis, and the treatment options used are very little effective. OBJECTIVE: To evaluate the therapeutic efficacy of the topical combination of benzoyl peroxide 5% and clindamycin 1% associated with sun exposure for the treatment of progressive macular hypomelanosis... CONCLUSION: The topical combination of benzoyl peroxide 5% and clindamycin 1% is effective in the treatment of progressive macular hypomelanosis.

Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, doubleblind, placebo-controlled trial. [Article in English, Portuguese] [2011]
treatment of progressive macular hypomelanosis... CONCLUSION: The topical combination of benzoyl peroxide 5% and clindamycin 1% is

more studies >>

Clinical Trials Related to Clinac (Benzoyl Peroxide Topical)

Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations [Completed]
A randomized, double-blind, multiple-site, placebo-controlled, parallel-group clinical study conducted to evaluate the bioequivalence of two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel formulations.

A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya� Topical Gel in the Treatment of Acne Vulgaris [Completed]
The objective of this study was to evaluate the efficacy and safety of Perrigo's test formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1. 2%/2. 5% compared to the already marketed formulation, Acanya gel in patients with acne vulgaris.

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study. The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0. 1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2. 5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study. The primary objective is to demonstrate the superiority in efficacy and assess safety of adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene topical gel, 0. 1% (adapalene monad); benzoyl peroxide topical gel, 2. 5% (benzoyl peroxide monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12 weeks.

A Long-Term Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]

more trials >>


Page last updated: 2016-04-29

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015